News

Secarna Pharmaceuticals and Vect-Horus have launched a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the blood-brain barrier (BBB) for…
Read More...

Transcend Therapeutics, a clinical-stage biotech focused on neuropsychiatric treatments, announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy…
Read More...

Merck Animal Health, a division of Merck & Co., Inc., announced the U.S. Food and Drug Administration (FDA) approval of BRAVECTO QUANTUM (fluralaner for extended-release injectable…
Read More...

Merck, known as MSD outside the U.S. and Canada, announced that it will acquire Verona Pharma plc in a $10 billion deal, strengthening its presence in the respiratory disease space. The…
Read More...

Indian pharmaceutical major Lupin Limited and pan-European drugmaker Zentiva Group have signed a license and supply agreement to commercialize Lupin’s biosimilar Certolizumab Pegol…
Read More...

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI),announced an exclusive licensing agreement for IGI's lead…
Read More...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully…
Read More...

Adcentrx Therapeutics, a clinical-stage biotech company specializing in Antibody-Drug Conjugate (ADC) therapies, announced that the U.S. Food and Drug Administration (FDA) has granted…
Read More...

Neuraxpharm Group, a leading European specialty pharmaceutical company focused on central nervous system (CNS) disorders, and Swedish R&D firm Dizlin Pharmaceuticals AB have…
Read More...

KalVista Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY (sebetralstat), a novel plasma kallikrein inhibitor, as the first and only…
Read More...

GSK plc has finalized its acquisition of efimosfermin alfa from Boston Pharmaceuticals, a promising investigational therapy targeting steatotic liver disease (SLD). Efimosfermin is a…
Read More...

Sagent Pharmaceuticals, a leading U.S. pharmaceutical provider, and China-based Qilu Pharmaceutical have entered a strategic partnership to commercialize a portfolio of complex…
Read More...

Chugai Pharmaceutical Co., Ltd., a major Japanese pharmaceutical company, and Singapore-based biotech firm Gero PTE. LTD. have announced a strategic joint research and license agreement…
Read More...

Mustang Bio, Inc., a clinical-stage biopharmaceutical company focused on cell therapies for hard-to-treat cancers, announced that the U.S. Food and Drug Administration (FDA) has granted…
Read More...

Swiss biopharmaceutical company BioVersys AG has entered into a global research and exclusive license option agreement with Japanese pharmaceutical firm Shionogi & Co., Ltd. to…
Read More...

Brii Biosciences Limited, a biotechnology company focused on addressing high unmet medical needs, has announced a licensing and technology transfer agreement with Joincare…
Read More...

Jazz Pharmaceuticals plc announced that the European Commission (EC) has granted conditional marketing authorization for Ziihera® (zanidatamab), a dual HER2-targeted bispecific…
Read More...

Merck, known as MSD outside the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License…
Read More...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ZEGFROVY (sunvozertinib), a novel oral therapy developed by Dizal, for the treatment of adults with…
Read More...

Adagene Inc., a biotechnology company developing innovative antibody-based cancer therapies, announced that Sanofi will invest up to $25 million in the company as part of an expanded…
Read More...